Objectives: There is no consensus regarding optimal follow-up in resected gastroenteropancreatic neuroendocrine tumours (NETs). We aimed to perform a practice survey to ascertain follow-up patterns by health care practitioners and highlight areas of variation that may benefit from further quantitative research. Methods: A Web-based survey targeted at NET health care providers in Australia, New Zealand, Canada, and the USA was developed by a steering committee of medical oncologists and a research methodologist. Thirty-seven questions elicited information regarding adherence to guidelines, the influence of risk factors on follow-up, and the frequency and choice of modality in follow-up. Results: There were 163 respondents: 59 from Australia, 25 from New Zealand, 46 from Canada, and 33 from the USA (50% medical oncology, 23% surgery, 13% nuclear medicine, and 15% other). Thirty-eight percent of the respondents were “very familiar” with the NCCN NET guidelines, 33% with the ENETS guidelines, and 17% with the ESMO guidelines; however, only 15, 27, and 10%, respectively, found them “very useful”; 63% reported not using guidelines at their institution. The commonest investigations used were CT scans (66%) and chromogranin A (86%). The US respondents were more likely to follow patients up past 5 years, and the Australian respondents utilized more functional and less cross-sectional imaging. When poor prognostic factors were introduced, the respondents recommended more visits and tests. Conclusions: This large international survey highlights variation in current follow-up practices not well addressed by the current guidelines. More quantitative research is required to inform the development of evidence-based guidelines tailored to the pattern of recurrence in NETs.

Keywords:
Follow-up, Neuroendocrine tumour, Surveillance, Survey
1.
Modlin IM, Öberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al: Gastro-enteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61–72.
2.
Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S: Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121: 589–597.
3.
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152–160.
4.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063–3072.
5.
Arnold R, Chen Y-J, Costa F, Falconi M, Gross D, Grossman AB, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90: 227–233.
6.
Öberg K, Knigge U, Kwekkeboom D, Perren A: Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(suppl 7):vii124–vii130.
7.
Clark OH, Benson AB 3rd, Berlin JD, Choti MA, Doherty GM, Engström PF, et al: NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw 2009; 7: 712–747.
8.
Singh S, Lawrence B, Chan DL, Pavlakis N, Segelov E; CommNETS: formation of an international Commonwealth countries NET partnership (abstract). Neuroendocrinology 2016; 103(suppl 1): 120.
9.
Rindi G, D’Adda T, Froio E, Fellegara G, Bordi C: Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007; 18: 145–149.
10.
Mosli HH, Dennis A, Kocha W, Asher LJ, Van Uum SHM: Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. J Clin Endocrinol Metab 2012; 97:E1731–E1735.
11.
Bech PR, Ramachandran R, Dhillo WS, Martin NM, Bloom SR: Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript. Clin Chem 2012; 58: 941–943.
12.
Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, et al: Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002; 23: 967–974.
13.
Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM: The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology 2015; 101: 1–17.
14.
Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES: The value of 68Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging 2014; 4: 426–434.
15.
Le Roux C, Lombard-Bohas C, Delmas C, Dominguez-Tinajero S, Ruszniewski P, Samalin E, et al: Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study. Dig Liver Dis 2011; 43: 828–833.
16.
Abrey LE, Louis DN, Paleologos N, Lassman AB, Raizer JJ, Mason W, et al: Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 2007; 9: 314–318.
17.
Hallet J, Law CHL, Karanicolas PJ, Saskin R, Liu N, Singh S: Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6,271 cases. Cancer 2015; 121: 2214–2221.
18.
Hallet J, Law CHL, Cheung M, Mittmann N, Liu N, Fischer HD, et al: Patterns and drivers of costs for neuroendocrine tumor care: a comparative population-based analysis. Ann Surg Oncol 2017; 24: 3312–3323.
19.
Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al: Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014; 311: 263–270.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.